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Tissue engineeringThe limited adequacy of animal cell cultures and models to mimic the complexity of human bodies in lab-
oratory conditions has emphasized researchers to find its quintessential bioelectronic alternative with
improved competence. In this regard, tissue engineering has emerged as one of the most precise bioma-
terial technologies in terms of creating new tissues to model vital organs. An organ-on-a-chip biosystem
has shown a plethora of applications in tissue engineering and drug delivery. Organ-on-a-chip is a
microfluidic device that provides a completely controlled microenvironment, similar to the natural tis-
sues for the cultured cells of an organ, by amalgamating cell biology and biomaterial science. The device
contains several microchambers and microchannels embedded in a layer of a biocompatible polymer,
such as polydimethylsiloxane. Microchambers house the cells, while microchannels provide nutrients
and growth factors. Over the past few years, organ-on-a-chip technology has displayed ample applica-
tions in the field of biomedicine, not only by simulating the normal functions of disparate organs, but also
by understanding the inter-relation between diversified systems. In this review, we have spotlighted
recent advancements and applications of organ-on-a-chip biosystems to construct physiological models
for the heart, lung, kidney, liver, and brain. Part of this review is also concentrated on abridging the des-
perate essentiality as well as future perspectives of organ-on-a-chip technology in biomedicine, disease
modeling, and drug development process.
 2021 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
At present, the conventional methods of drug development by
pharmaceutical industries are facing unprecedented challengesnot only due to the escalating costs but also irrefutable implemen-
tation of extensive pre-clinical trials (Eftekhari et al., 2019). The
use of animal cell culture techniques has often become unsuccess-
ful to mimic the complexity of human bodies and is unable to
model situations where organ-organ and tissue-tissue communica-
tions are significant (Mittal et al., 2019). Despite certain efficacy in
animal models, the elucidation of the precise mechanism of action
of drugs is often difficult, which leads to misleading observations
and data. In the past, traditional two-dimensional (2D) cell cultures
system had established a pivotal platform for extensive life science
studies and showed colossal contributions in the medical system
by reducing the utilization of animal models. Unfortunately, these
techniques failed to simulate the physiological expressions of liv-
ing cells and did not facilitate studying the microenvironment of
tissues or the inter-relationships between disparate tissues and
organs of humans (Rajan et al., 2020). Considering the certain inef-
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cal necessity for novel testing strategies and intermediate human
in vitromodels in the early phase of the drug development process,
for predicting a molecule’s or a test drug’s effectiveness and safety
in humans that could diminish the adverse impacts observed in
different pre-clinical trial phases.
Over the past few years, organ-on-a-chip, lab-on-a-chip, or
tissue-on-a-chip systems have emerged as one of the most promis-
ing tissue engineering technologies, which include findings from
material science and biological systems (Jodat et al., 2019). This
biomimetic technology is considered as an auspicious alternative
to the conventional approaches of the drug development process,
because it aims to mimic the functional attributes as well as phys-
iological conditions of tissues and organs by regulating disparate
parameters (Wu et al., 2020). The system is prepared on a microflu-
idics chip, which constitutes perfused chambers filled with living
cells, simulating the physiology of tissues and organs (Bhatia and
Ingber, 2014). The device consists of several microchambers and
microchannels embedded in a layer of polymer, most commonly
polydimethylsiloxane (PDMS) polymer. This polymer is mainly
used due to its unique transparency and biocompatibility proper-
ties. Microchambers house the cells, while microchannels provide
nutrients and growth factors. To improve the cell culture medium
and cell adhesion, the chip surface is coated with the materials
derived from the extracellular matrix (Wu et al., 2020). For a
detailed study, various types of biosensors, digital sensors, imaging
devices, and microelectrodes are installed on the chip. Usually,
nutrient transfer and waste disposal are done by creating a contin-
uous flow in the microchannels. At the same time, the flow-
pressure values and dynamic changes of the cells are measured
and controlled using different sensors (Shay, 2017).
This emerging technology not only provides paramount infor-
mation about the morphology and differentiation of cells but also
induces gene expression and cellular functions (Mittal et al.,
2019). Most importantly, the organ-on-a-chip system exhibits
unique potentiality to reduce the utilization of animal models,
and even human beings in the development process of novel drug
candidates (Zhang et al., 2018). The system offers pronounced ther-
apeutics for disparate types of infectious, cardiovascular, neurolog-
ical, and metabolic diseases (Shay, 2017). Recently, during the
coronavirus disease-19 (COVID-19) pandemic, this system was
implied for obtaining fast and reliable outcomes towards the treat-
ment process (Monteil et al., 2020).
Nanoparticle-based drug delivery systems have offered incred-
ible potential in the treatment of different diseases including can-
cer (Maleki Dizaj et al., 2019). However, the clinical application of
nanomedicine is limited due to the problems in controlled drug
release in relation to high batch-to-batch differences, inadequate
synthesis rate of the conventional preparation techniques and
the lack of delivery monitoring technologies for nanomedicines
in correlation with animal tests (Ejeta, 2021). The microfluidic
technology might bring new hopes in the elimination of these chal-
lenges, as they can generate nanoparticles with high controlling
capability, reproducibility and efficacy as well as creating 3-D envi-
ronments to simulate cellular processes (Ejeta, 2021).
Considering the cutting-edge researches in microfabrication
technology and the desperate necessity of microfluidics techniques
for human health, this review spotlights the recent advancements
of the organ-on-a-chip system and its role in precision medicine as
a future rational drug development approach.
2. Design concept and components of the organ-on-a-chip
system
Controlling the external and internal cellular environment is
imperative for the dynamic activity of the cell culture system. Dif-2
ferent parameters and physiological environments are often con-
trolled by the co-action of micromachinery and cellular biology
(Bhatia and Ingber, 2014). The fluid shear stress, concentration gra-
dient, mechanical stress, and cells patterning are primarily consid-
ered for the physiological functioning of the chip.
The dynamic nature of culture cells is enabled by microfluidics
through micropump perfusion. It is known to administer essential
nutrients and excrete waste materials. Fluid shear forces induce
the polarity of organs. The organ-on-a-chip system applies essen-
tial pressure on endothelial cell functionality by stimulating signal-
ing molecules. In a like manner, the fluid added into the organ-on-
a-chip system allows biological activities at the organ level
(Haddrick and Simpson, 2019). The fluid causes the formation of
stable gradients of molecules at the microscale level. The concen-
tration gradients induce biochemical signals, causing the process-
ing of different biological phenomena. Complex physiological
process is stimulated by microfluidics in the human body. It alters
the flow velocity and achieves biochemical concentration gradients
(Yang et al., 2014). Pressure in the blood vessels of the human body
is the major indication of stress levels in the vital organs and tissue.
This system uses elastic porous membranes for creating dynamic
mechanical stress, which is considered an important factor of dif-
ferentiations during the physiological process (Yang et al., 2017).
Ordered arrangements of cells are essential for forming a func-
tional body. Cell patterning on the chip is carried out by surface
modification, template, and three-dimensional (3D) printing.
Among them, the 3D printing technique shows multi-scale cells
patterning by forming hydrogel scaffolds with the complex chan-
nel. Most importantly, 3D printing provides versatility in the cellu-
lar pattern, which is critical for in vitro reconstruction of the
cellular microenvironment (Wu et al., 2020).
Microfluidics, living cell tissues, simulation, and senses are the
most important components of an organ-on-a-chip system.
Microfluidics helps deliver targeted cells towards a pre-designed
location and constitutes fluid input and waste liquid release. The
living cells tissues component aligns a specific cell type in a 2D
or 3D system. Hydrogels are generally used to create 3D systems.
Despite more accuracy of 3D tissue structures, living cells tissues
are extensively cultivated in the 2D system due to the cost limita-
tions and vasculature formation. The physical or chemical signal is
essential for simulating the microenvironment for some tissues.
Various signal stimuli can be observed from drug-screening pro-
cesses. The detection and compilation of data are done by the sens-
ing component (Wu et al., 2020).
Mitochondria as distinct organelles in mammalians may form
organized tubular network that are continually changing under
specific conditions including mitophagy or biogenesis, separation
(fission) and fusion (Ahmadian et al., 2017; Fard et al., 2016). Pre-
vious studies showed that organ-on-a-chip devices can monitor
the mitochondrial dysfunction dynamics and therefore simulates
real-time organ damage (Clapp et al., 2021). For example, the levels
of lactose and glucose in the liver chip could be measured via con-
trolling microfluidic alteration (Cong et al., 2016).
The cell viability and metabolic activity are markers of mito-
chondrial function in relation to the oxidative phosphorylation
process (Eftekhari et al., 2016). Moreover, screening of the toxicity
and efficacy of drugs/xenobitoics is possible using liver chips (Cong
et al., 2016). Microfluidic bead electrochemical immunosensors
have been used to detect cell-released biomarkers along with liver
chips. The applied system exhibited high accuracy and efficiency
(Cong et al., 2016).
3. Organ-on-a-chip devices
Studying different biological barriers is a pivotal step to under-
standing the pharmacology of drugs. Researchers have developed
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partments to mimic varied biological barriers viz. blood–brain bar-
rier, kidney transport barrier, and the lung’s alveolar-capillary
interface. Recent discoveries in membrane and muscular thin films
for recapitulating the physicochemical interface of different organs
are discussed below:
3.1. Kidney-on-a-chip (KOC)
The kidney is an active metabolic organ and is involved in glu-
coneogenesis, erythropoietin, and renin synthesis. It is also the site
of clearance for the drugs. The kidneys control body fluid balance
and excrete waste products through three mechanisms: filtration,
reabsorption, and secretion. The functional unit of the kidney is
the ‘nephron’ which consists of the renal corpuscle (filters blood
plasma), and the renal tubules that are involved in the reabsorp-
tion and secretion of substances. The kidney performs its hemo-
static mechanism through the activity of different tubular parts
of the nephrons (Feher, 2017). However, renal tubules are comple-
mentary in reabsorption and secretion of substances, but the role
of proximal tubules is more important than other tubules. Proxi-
mal tubules reabsorb approximately three-fifth of the filtered
water, salt, glucose, amino acids, and low molecular weight pro-
teins. These tubules play a fundamental role in the acid-base bal-
ance process by reabsorbing four-fifth of the filtered bicarbonate.
This reabsorption occurs due to the presence of pumps and chan-
nels in the basolateral (facing the interstitial space) and apical (fac-
ing the tubular lumen) membrane (Zhuo and Li, 2013). The distal
tubule helps homeostasis of sodium, potassium, and divalent
cations with 5–10% sodium and chloride reabsorption. It also helps
in the secretion of potassium cations and maintains the systemic
balance of magnesium and calcium (McCormick and Ellison, 2015).
Nephrons remove waste products from the body by filtering
180 L of blood plasma. This ultrafiltration and high fluid flow in
the tubules exposes the apical surface of the nephron cells to the
shear stress of the fluid (Raghavan et al., 2014). Fluid shear stress
causes the polarity of nephron cells through the expression of dif-
ferent genes and thus the reorganization of the cytoskeleton (Jang
et al., 2011). In humans, fluid shear stress is estimated from 0.7 to
1.2 dyne/cm2. The apical surface of the proximal tubule cells is con-
tinuously exposed to fluid shear stress and osmotic pressure. These
cells detect the high flow of tubular fluid by apical surface sensors,
send messages into the cell to reorganize the connections and
cytoskeleton, and increase apical endocytosis (Raghavan and
Weisz, 2015).
The KOC model represents the use of cell culture on a chip that
is similar to the microenvironment of the kidney. The KOC model
allows the culturing of renal cell types and provides cell–cell func-
tional communication (such as the interaction between endothelial
cells and podocytes in the renal corpuscle), expression of different
membrane carriers, and normal endocrine and metabolic functions
(Wilmer et al., 2016). KOC models may be used to screen and test
drug toxicity, study glomerular filtration processes, analyze differ-
ent parts of the nephron, and determine pharmacokinetics as well
as the effective dose of the drug. Because the model is very similar
to the human condition, it predicts more accurately the physiolog-
ical processes and drug-induced renal toxicities and reduces the
number of animals used in the clinical trials. Various models of dif-
ferent parts of the nephron (glomerulus, proximal, and distal
tubule) have been designed, but a complete model of nephron-
on-a-chip that integrates these components has not yet been
developed. Currently, most KOC models based on microfluidic sys-
tems rely on three main structures: (i) single-layer systems, (ii)
multilayer systems consisting of two chambers separated by a per-
meable membrane, (iii) systems made up of a single straight pipe
structure, and (iv) systems consisting of a tubular structure with3
a vascular network. Among these systems, cell culture is the main
focus of the design. Cell culture is 2D in monolayer systems and 3D
in others. The design of these systems enables the researchers to
study and create several functions from various parts of the
nephron.
The development of KOC systems that mimic different physio-
logical compositions and the environmental situation has the pos-
sibility of its colossal applications in the medical field. To simulate
and reconstruct different environmental conditions, KOC systems
must simultaneously consider five attributes of renal physiology:
(i) tubular fluid flow mode, (ii) cell-matrix interaction with tubular
microenvironments (such as extracellular matrix and growth fac-
tors), (iii) biophysical properties associated with tubular microen-
vironments, such as mechanical stiffness and porosity, (iv)
multidimensional geometric properties of individual renal tubules
(such as size and local and general curvatures), and (v) cell–cell
and tissue-tissue relationships due to the structural organization
of adjacent separate renal tubules (Sochol et al., 2016).
3.1.1. Glomerulus-on-a-chip (GOC)
The glomerulus is the filtering part of the nephron, which con-
sists of a capillary network, basement membrane, and podocytes.
By selectively filtering the blood, the glomerulus produces a fil-
trated liquid and eventually urine (Greka and Mundel, 2012). The
design of an in vitro model that simulates the function of the
glomerular filtration barrier is of immense interest to investigators.
The filtration barrier has selective permeability and is always
exposed to shear stress due to the liquid flow.
A GOC model was designed to study hypertensive nephropathy.
In this model, endothelial cells and podocytes form two cell layers
which are separated by a thin membrane coated with an extracel-
lular matrix, thereby simulating the structure of a glomerulus. This
model successfully simulated cytoskeleton rearrangement, cell
damage, and glomerular leakage with the fluid flow (Zhou et al.,
2016). Another GOC model was designed to study diabetic
nephropathy. This model contained a glomerular filtration barrier
that was affected by the fluid flow and produced pathological
responses to high glucose (Wang et al., 2017a; Wang et al.,
2017b). Recently, a GOC device used podocytes differentiated from
the pluripotent human-derived stem cells. These podocytes, when
cultured with human glomerular endothelial cells in a microfluidic
apparatus, produce glomerular basement membrane collagen and
mimic the interaction of normal glomerular tissues and different
albumin and inulin clearance (Musah et al., 2017).
In a different study, the glomerular filtration barrier was mod-
eled on GOC using co-cultures of human glomerular endothelial
cells and podocytes. This model consisted of two vascular and uri-
nary channels. There is a type-1 collagen layer between the two
channels. Podocytes, basement membrane, and glomerular
endothelial cells are located on the collagen layer. In long-term cul-
ture, the cells retained their morphology, formed capillary-like
structures, and expressed cleft diaphragm proteins. This system
simulated the structure and functions of the glomerulus (such as
selective infiltration). When the filtration barrier of the glomerulus
was exposed to the serum of patients with anti-podocyte antibod-
ies, the chips showed that the amount of albuminuria was propor-
tional to the proteinuria of the patients. Using this chip, it is
possible to study the pathophysiology of the glomerulus, identify
other therapeutic targets, and screen high-throughput therapeutic
compounds (Petrosyan et al., 2019).
3.1.2. Proximal tubule-on-a-chip (PtOC)
The first site of drug clearance and the front line against drug
toxicity in nephrons is the proximal tubule. Therefore, it is very
important in the clinical evaluation of drug compounds. An essen-
tial aspect for accurate simulation of proximal tubule function
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molecules (Ng et al., 2013). Specific carriers and pumps on both
sides of the basal and apical sides of the proximal tubules transfer
organic cations and anions, as well as supply a mechanism for the
excretion of biological and endogenous substances (Jacobsson
et al., 2007).
In another PtOC model, human epithelial cells of proximal
tubule were implanted in the upper surface of the polyester mem-
brane coated with the extracellular matrix. The polyester mem-
brane separated the main chamber of the chip into apical and
basal chambers. In this study, cells exposed to the fluid shear stress
(dynamic culture conditions) acquired specific physiological prop-
erties such, as polarity, primary cilia, columnar shape, and func-
tional carriers. While cells were cultured under static conditions,
they did not acquire these characteristics. Therefore, creating static
and dynamic culture conditions in a platform can simulate tissue
physiological processes effectively (Jang et al., 2013) (Fig. 1A-C).
Hollow fibers may be used as scaffolds for cell culture and imi-
tation of renal tubules due to their tubular shape. Proximal tubular
epithelial cells have a key role in the reabsorption of ions and pro-
teins that have passed through the filtration barrier of the
glomerulus. The proximal tubule cells contain lots of megalin
and colin multi-ligand receptors, which effectively absorb low
molecular weight proteins and other ligands from the filtered fluid.
Megaline and cubilin bind to vitamin-carrying proteins to reabsorb
them. Impaired absorption of these proteins leads to vitamin defi-
ciency (Eshbach and Weisz, 2017). In one model of PtOC, human
epithelial cells of proximal tubule were cultured on the inner sur-
face of hydrogel-coated hollow fibers. The cells cultured on the
inner surface of the hollow fibers formed a functional transfer
layer, which was demonstrated by albumin reabsorption and the
secretion of albumin-bound uremic toxins (Jansen et al., 2015;
Jansen et al., 2016). In a microfluidics device, human epithelial cells
of proximal tubule were cultured in a tubular structure surrounded
by a chamber. In the study of the physiological activity of this
device, the transport of substances at the basal and apical levels,
cellular polarity and morphology, and function of intracellular
enzymes were well demonstrated (Weber et al., 2016) (Fig. 1D-F).
Bioprinting is an alternative method of making PtOC (Sochol
et al., 2016). In one model of PtOC, the structural components ofFig. 1. (A, B, and C) KOC design using a porous membrane located between two chambe
upper and lower chambers, respectively, and (D, E, and F) KOC design using hollow fiber.
were perfused by a tubular fluid stream and the chamber around the hollow fiber by a
4
the proximal tubule were designed using bioprinting, in which
the tubules were first printed on an extracellular matrix of
gelatin-fibrinogen using volatile ink. Further, an additional extra-
cellular matrix was poured around the printed design. After drain-
ing the volatile ink, a hollow tube was formed. Proximal tubule
cells were implanted in a hollow tube and perfused for a long time.
This system was stable for 2 months which indicates the durability
and survival of cells. Thus, this system has the potential to improve
and build other organ-on-a-chip systems (Homan et al., 2016). In
another model of PtOC, a proximal tubule containing epithelial
cells, endothelial cells, and renal fibroblasts were designed using
bioprinting. This model which mimicked the features of renal
fibrosis was stable for at least 30 days. This model used proximal
tubule cells along with several types of renal interstitial cells to
investigate cell–cell interaction and paracrine signaling between
constituent cells. This model also can confirm key physiological
aspects of the proximal tubule, diagnose renal toxicity, and evalu-
ate renal fibrosis (King et al., 2017). In another study, using this
type of design, two channels were created side by side on an extra-
cellular matrix substrate. The epithelial cells of the proximal tubule
were cultured in the first canal, and vascular endothelial cells were
cultured in the second canal and perfused independently using a
closed-loop system to evaluate the reabsorption of the renal
tubule. This model showed active reabsorption through the
tubular-vascular exchange of salts. The epithelium-endothelium
relationship was also investigated by placing the epithelial cells
of the proximal tubule in the hypoglycemic conditions (Lin et al.,
2019) (Fig. 2).3.1.3. Distal tubule-on-a-chip (DtOC)
So far, the use of DtOC model is very limited. Dog kidney cells
were first used to make DtOC. In this model, the cells were cultured
inside polydimethylsiloxane microchambers coated with fibronec-
tin. Tiny ducts connect the culture chambers to a fluid circulation
system but disrupt cell proliferation and survival at flow rates sim-
ilar to in vivo conditions (50 lL/min) (Baudoin et al., 2007). A DtOC
model was designed for the analysis of renal tubular cells using a
microfluidic canal, a porous membrane, and central collecting duct
cells of rat kidneys. After culturing the cells in the canal to simulate
the tubular environment in vivo, the cells were exposed to a shearrs. Renal tubular epithelial cells and vascular endothelial cells were cultured in the
Renal tubular epithelial cells were cultured inside the hollow fiber. The hollow fibers
medium.
Fig. 2. Making a KOC using bioprint technology. (A) steps of making a KOC using a bioprint, (B) PtOC model using only proximal epithelial tubule cells, and (C) PtOC model in
which proximal epithelial tubule cells were used along with vascular endothelial cells.
S. Seidi, A. Eftekhari, A. Khusro et al. Journal of King Saud University – Science 34 (2022) 101710stress of 1 dyne/cm2 for 5 h to provide optimal fluid conditions for
the cultured cells. These conditions increase cellular polarity and
reorganize the cytoskeleton. This device simulates renal tubules
in vivo and can be used specifically in drug screening and tissue
engineering (Jang and Suh, 2010).
Microfluidic systems evaluate the physiological functions of
biological components under in vivo and in vitro conditions. These
systems are created on the micrometer scale and contain micro-
liter scale materials. A KOC system is a microfluidic system
designed to examine at least one physiological variable of a kidney
on a platform. The material of these platforms is mainly polymer
and biocompatible, and cells of one organ or tissue are easily cul-
tured on it. For optimal cell adhesion, the polymer surface is
mainly covered by an extracellular matrix component. A platform
is a plate made primarily of polymer on which chambers are
designed for cell culture, tissue or organ maintenance, and reser-
voirs for medium flow. On this plate, various biosensors are
installed to measure and evaluate physiological variables. The
plate is generally clear and transparent, and changes can be easily
captured with a confocal microscope. Although 2D models and
some 3D models may be useful in screening drug compounds, they
cannot completely simulate the physiological condition of an
organ. These models are mostly designed from the beginning to
study the effect and determine the toxicity of drug compounds. If
the purpose of designing these models was to study the function
and knowledge of physiological mechanisms to build new organs
for transplantation into the human body, success and results
would be far more practical and effective.
3.2. Lung-on-a-chip (LuOC)
For the first time, a LuOC model was designed using soft lithog-
raphy technique on polydimethylsiloxane polymer. A thin mem-
brane (10 lm), coated with an extracellular a matrix was placed
between the upper and lower microchannels. Human alveolar
epithelial cells and lung endothelial cells were cultured in the
upper and lower parts of this membrane, respectively. When the
alveolar cells were connected, an air-fluid interface was created
on the surface of the alveolar cells by circulating air in the upper
channel. In the lower vascular canal, a constant medium current5
was maintained. The use of a periodic vacuum in two side hollow
chambers resulted in regular mechanical tension of the lateral
walls (flexible polydimethylsiloxane polymer) and the central por-
ous membrane. The tension of the central porous membrane
together with the cell layers attached to it mimics physiological
respiratory movements (Huh et al., 2010). Using the same method,
another microfluidic lung model was designed that contained air-
way epithelial cells (air-fluid interface), vascular endothelial cells,
and lung fibroblasts cultured in three vertical sections. Each verti-
cal part was separated by a nanoporous membrane (Sellgren et al.,
2014). In another model, a reversible alveolus-on-a-chip model
was designed to simulate the pulmonary parenchyma microenvi-
ronment. A micro diaphragm was used to simulate in vivo
diaphragmatic movements and dilation of the alveolar wall (respi-
ratory barrier) (Stucki et al., 2015) (Fig. 3 A-C).
A lung airway-on-a-chip model was designed to simulate the
airway microenvironment and analyze the interaction of epithelial
cells and airway smooth muscle with the extracellular matrix. The
microdevice consisted of three vertical microfluidic chambers (lay-
ers), an upper chamber for culturing epithelial cells (air-fluid inter-
face), a thin middle hydrogel layer, and a lower chamber for
culturing airway smooth muscle cells. The device is completely
assembled after the solvent is added to three different layers of
polymethyl methacrylate (Humayun et al., 2018). An airway-on-
a-chip model containing a vascular network was designed using
3D cell printing. In this model, an avascular platform using
endothelial cells, lung fibroblasts, polycaprolactone, and poly-
dimethylsiloxane polymer was printed directly in a three-
dimensional aspect on the extracellular matrix. The platform con-
sisted of a central microchamber and two lateral microchambers
for culturing epithelial cells and lung fibroblasts. These
microchambers were separated by microchannels to create a
media stream and an area for connecting the polydimethylsiloxane
polymer to the top polydimethylsiloxane chip. In this model, the
airway successfully established a functional connection with the
vascular network (Park et al., 2018a; Park et al., 2018b).
Researchers have developed various models to mimic the phys-
iological functions within the chips. The presence of air in the
epithelial chamber and the exposure of cultured cells to air as com-
pared to cultured cells exposed to fluid, increases cell survival, pul-
Fig. 3. LuOC model. (A) the chip is made by engraving chambers and channels on a polymer platform, (B) cross-section of the chip, (C) connecting the chip to the pump and
receiver, and (D, E, and F) alveolar-on-chip which mimics respiratory movements (cyclic strain) using micro diaphragm on the chip. Medium flow is regulated by valves. As
the micro diaphragm is stretched, air enters the upper chamber. Note: Figures match the original models in terms of functionality but do not match in appearance.
S. Seidi, A. Eftekhari, A. Khusro et al. Journal of King Saud University – Science 34 (2022) 101710monary surfactant production, the electrical resistance of different
tissue layers, and structural integrity and permeability of the nat-
ural barrier (Benam et al., 2017; Hiemstra et al., 2019). Structural
and functional simulation of a model and its approach to the nat-
ural state improves the results. For example, in one model, expos-
ing the alveolar epithelial cells (respiratory barrier) and airway
epithelial cells to airflow and cyclic strain better mimic pulmonary
physiological conditions and also improves the interaction and
function of different parts of the pulmonary microenvironment
(epithelial surface, basement membrane, and vascular surface).
Simulation of lung alveoli in vitro is difficult due to the complex
architecture of the dynamic lung environment. The alveolar wall
with only a few micrometers thickness is an extremely thin barrier
between air and blood in vivo. It constitutes tight and semi-
selective layers of epithelial cells (forming the alveolar wall),
endothelial cells (forming the endothelial wall), and base mem-
brane. The alveolar wall expands and contracts rhythmically to
allow air to enter and exit the alveoli. Many in vitro models are
designed to simulate the alveolar barrier of the lung in vitro, but
only a few models use mechanical forces for respiratory move-
ments (Konar et al., 2016; Bhowmick and Gappa-Fahlenkamp,
2016).
In 2010, a microfluidic system was developed that simulated
diaphragmatic action. The device contained a thin porous elastic
membrane (resembling an alveolar barrier) in which alveolar
epithelial cells were cultured on the apical side of the membrane
and endothelial cells were cultured on the basal side of the mem-
brane. This alveolar barrier was periodically stretched in one direc-
tion to simulate diaphragmatic breathing movements (Huh et al.,
2010) (Fig. 3D-F). In another model, respiratory movements were
simulated by periodic deformation of the micro diaphragm, similar
to the diaphragmatic movements in vivo. In this model, alveolar
epithelial cells of a patient’s lung were cultured on a device under
physiological mechanical strain (Stucki et al., 2015). The alveolar
model was used to simulate pulmonary thrombosis, primary alve-
olar epithelial cells, and lung endothelial cells. But in this model,
the cells were not subjected to cyclic strain (Jain et al., 2018). In
another alveolar model, the system automatically provided a pas-6
sive medium flow at selected time points. Unlike previous models,
the new alveolar model is equipped with a passive medium
exchange that not only reproduces periodic mechanical stress
but also allows long-term cell culture between air and fluid. There-
fore, specific features of the lung microenvironment are simulated
more accurately. These features have important effects on many
biological processes, such as differentiation and polarity of epithe-
lial cells, which play a key role in identifying physiological pro-
cesses (Ravasio et al., 2011; Hobi et al., 2012).
3.3. Heart-on-a-chip (HOC)
Statistical studies have shown that drug toxicity is the prime
reason for halting the development and production of drugs.
Enhancing the efficacy of cardiovascular drugs and ensuring drug
safety are important factors in the drug screening process (Ferri
et al., 2013). Animal models and 2D cell cultures are common
methods in the drug development process (Pirzad Jahromi et al.,
2015). But they are inadequate and inefficient to simulate human
physiological mechanisms. One of the most advanced methods
for evaluating heart function and drug screening is the HOC model
(Sidorov et al., 2017).
Biofabricating 3D heart tissues from cardiomyocytes [derived
from human induced pluripotent stem cells (iPSCs)] are a suitable
method to screen personalized medications. Vascularization of the
heart tissue is necessary for the survival of cardiomyocytes
because the arteries provide nutrients and eliminate metabolic
waste products. Combining HOC with microfluidics simulates true
biology and physiology in vivo by creating a circulatory or distribu-
tion system (Raasch et al., 2015).
Contractile behavior is the most important feature of cardiac
function and it can be an important criterion for evaluating drug
safety and efficacy during screening. Also, it is an indicator of car-
diac functions that comprise variables such as contraction fre-
quency, force, and synchronization over time. Until now, several
reports have been published to evaluate contractile behavior with
HOC (Zhang et al., 2017a; Zhang et al., 2017b). The main method
for evaluating contractile behavior is the detection of deformation
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ocyte culture medium, the contractile behavior is calculated by
stretching a traction-sensitive sensor (Lind et al., 2017). The con-
tractile behavior of cardiac muscle is measured on HOC by
microsensors such as microcantilever of an atomic force micro-
scope and pillar arrays. These microsensors are stimulated by the
deformity caused by the contraction of cardiomyocytes. Pillar
arrays are microsensors that are sensitive to pressure and tension
and bend by force. They are implanted regularly and attached to
the cardiac myocytes in a culture medium or HOC model. Contrac-
tion of myocytes causes displacement of pillar arrays. The contrac-
tile force can be calculated by measuring the amount of
displacement or curvature of pillar arrays (Ribeiro et al., 2016).
The microcantilever of an atomic force microscope is a tiny sensor
that creates tiny indentations inside the tissue. This device acts as a
probe to detect the deformation of the heart tissue and also causes
synchronous contraction by sending stimulus messages in differ-
ent sizes and frequencies. Increasing the frequency and amount
of indentation significantly increases the contraction rate (Galie
et al., 2015) (Fig. 4).
The image processing system can analyze the contractile behav-
ior of myocytes in the HOC model using a video recording system.
Sensors or other devices (endoscopes) may be used to improve the
efficiency of this system (Kim et al., 2011). In a recent report, a HOC
model was developed containing a microchannel and cell culture
chamber equipped with intracellular and extracellular bioelec-
tronic devices. This model can mimic coronary occlusion diseases
by changing the temporal oxygenation of the cell culture medium
under normoxic, hypoxic, and recovery/perfusion conditions. This
model may also accurately record electrical activity inside and out-
side the cell using various bioelectronic devices. For example, these
devices can detect the initial period of tachycardia by detecting a
decrease in the level of oxygen in the fluid inside the device. The
design of this model or platform represents progress in under-
standing electrophysiological responses in different states of heart
function and can be used in disease modeling and drug develop-
ment (Liu et al., 2020). A model designed to study live and simul-
taneous cardiac contractile behavior uses image processing and
piezoelectric sensing systems to identify the contractile behaviorFig. 4. Two types of HOC models to measure the contractile behavior of cardiomyocytes
fabrication of a HOC model using sensory elastic microfilm.
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of a unit and the whole heart tissue, respectively. Measurements
with two different systems provided complete information about
the evaluation of the cardiac tissue’s contractile behavior
(Sakamiya et al., 2020). The use of these two HOCs from bioelec-
tronic and biomechanical devices has resulted in the optimal
recording of the electro-mechanical activity of cardiac myocytes.
The major concern is how to use electrical and mechanical sensors
on these two devices without affecting the quality of data record-
ing. Engineering the installation of sensors without any defects in
data recording and cell damage is a significant step in the progres-
sion of other HOCs.
Recent HOC systems have efficiently simulated the structure
and function of the normal heart muscle. These are also potent
devices for modeling heart diseases. But the process of connecting
and merging different measuring instruments and different sen-
sors on one organ chip is difficult, in addition, to damaging the
cells. Therefore, current devices are not suitable for examining
the electrophysiological processes of the heart.3.4. Brain-on-a-chip (BrOC)
The most complex organ in the human body is the brain and
together with the spinal cord, it forms the central nervous system
(CNS). The brain receives, interprets, mixes, and harmonizes infor-
mation and then controls the activity of each organ of the body by
sending appropriate signals. The brain consists of a large number of
neurons that communicate unilaterally through synapses, where
the axon end of one neuron communicates with the dendrites
and the cell body of another neuron in a special direction
(Swanson and Lichtman, 2016). In addition, the neurons communi-
cate with other neural cells such as oligodendrocytes, astrocytes
and microglia (Jäkel and Dimou, 2017). The most important feature
of neurodegenerative disorders (Alzheimer’s and Parkinson’s dis-
ease) is the progressive cell death of parts of the brain. Parkinson’s
disease causes synaptic changes and neurons death in the corticos-
teroid network. On the other hand, Alzheimer’s disease causes neu-
ritis, neurons death, and deposition of neurotoxic protein plaques.
These diseases mainly affect humans and the only way to study
them is through animal models and to examine the brains of the. (A, B, and C) fabrication of a HOC model using the nanopillar array and (D and E)
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human models in studying the mechanism of action and drug
screening (Pirzad Jahromi et al., 2012). Because of the ethical prob-
lems associated with the use of animal models, very limited infor-
mation has been obtained about the mechanism and progression of
these diseases (Franco and Cedazo-Minguez, 2014; Lage et al.,
2018).
Recently, many advances in BrOC technologies have been made
using a simulated blood–brain barrier (BBB) and neural circuits in
engineered models. So far, five types of BrOC models have been
designed to study the components of brain tissue and drug screen-
ing: (i) models that study BBB using cultures of nerve and endothe-
lial cells in two chambers separated by a porous membrane, (ii)
models that study different parts of neurons (cell body and axons)
by dividing the culture medium into separate sections, (iii) models
that study the components of brain tissue on a hydrogel, by study-
ing the cell-matrix and cell–cell communication with three-
dimensional printing, (iv) models that study the interaction of dif-
ferent cells by merging multiple chips and creating a medium flow
between them using a pump, and (v) models that are used in high-
throughput screening studies by integrating advanced BrOC mod-
els with traditional models (Bang et al., 2019).
The brain and spinal cord are made up of different neurons and
glial cells. So far, no model has been proposed to simulate the com-
plete structure and function of the brain. But it is possible to sim-
ulate part of the brain or part of brain processes using existing
techniques. Therefore, the plasticity and connection of neurons in
the neural network, the function of the BBB, and the myelination
process of neurons on an engineered and isolated system can be
examined independently. With the advent of cell culture technol-
ogy, neurons could be cultured in vitro, and with the invention of
soft lithography, cell culture was performed in a microphysical
environment, such as microchannels (Whitesides et al., 2001).
Later, using multistage lithography, microchannels of different
heights and widths were fabricated on a BrOC. It was also possible
to separate the soma and axon physically using this technology. By
constructing microchannels at high and low levels on a BrOC and
by placing neurons on it, soma and axons are placed in the upper
and lower microchannels, respectively. Therefore, it is possible to
study a soma and an axon independently (Park et al., 2009; Kim
et al., 2016). By dividing a platform into separate parts and placing
a neuron in these separate parts, different portions of the neuron
can be examined independently. In addition, engineering and mod-
ifying the geometry of channels (through which only axons pass)
allows for one-way axonal growth. In this way, axonal growth,
direction, and axonal communication can be examined more care-
fully (Jadhav et al., 2016; Paranjape et al., 2019).
The most important function of the nervous system is to coor-
dinate different organs by receiving sensory messages, processing,
and sending motor commands. The speed of signal transmission
plays an important role in the functioning of the nervous system
and the coordination of different organs. The myelination of neu-
rons increases the speed of signal transmission. Impaired myelin
production leads to neurodegenerative diseases such as multiple
sclerosis. Simulation of the myelination process in BrOC is one of
the effective techniques in the basic studies related to myelination.
The BrOC chips allow the direct study of axon myelination under a
microscope due to their transparency (Kerman et al., 2015). There-
fore, increased myelin production and differentiation of oligoden-
drocytes can be observed under a microscope by applying
electrical and optical stimulation to a compartmentalized BrOC
system (Lee et al., 2017).
Selective permeability of the blood–brain barrier (BBB) leads to
normal brain function. This structural barrier facilitates the entry
of necessary nutrients and the removal of waste products. It also
prevents the entry of neurotoxins and large hydrophilic molecules8
and the invasion of pathogens (Pardridge, 2009; Daneman, 2012).
Many drugs developed to treat neurological diseases often fail
and are avoided during the drug screening process due to lack of
transmission from the BBB and entry into brain tissue (Liu et al.,
2012).
A microfluidic model with a porous membrane was designed to
show how materials are transported through the BBB. The pres-
ence of pores in this membrane causes the cells in two microchan-
nels to communicate with each other through the membrane pores
in a cytokine-dependent manner. This BrOC simulates the struc-
ture of the BBB (Brown et al., 2015). The BBB trans-endothelial
electrical resistance can be measured by placing one electrode in
each channel (Wang et al., 2017a; Wang et al., 2017b). When cells
cultured in two microchannels attach to the lateral surfaces of a
porous membrane, 2D cell culture media become 3D. The interac-
tion between different cells on both sides of the pores (endothelial
cells and astrocytes) is established in the form of physical contact
(direct) and chemical contact (indirect). In physical contact, two
cells on either side of the membrane connect through pores, but
in chemical contact, two cells communicate with each other
through chemicals in the form of paracrine (Vatine et al., 2019)
(Fig. 5).
An important point in modeling 3D neural circuits is how axons
are positioned in the 3D environment. In early models, neurons
were placed between walls to study neuronal growth accurately.
In this case, the neural network created was very limited. But in
newer models, neurons are planted in the hydrogel substrate.
The neural network and the vascular network created in the hydro-
gel substrate simulate the microstructure of neural tissue effec-
tively. Models, in which components of the nervous system are
implanted in the hydrogels, simulate the function and the struc-
ture of nervous tissue well. The vessels made in this bed are similar
to the vessels of the body. Also, the relationship of the vascular sys-
tem with the neural network created in this hydrogel substrate is
functionally and structurally very similar to the neural tissue.
These models are called high content models (Uwamori et al.,
2017). In the previous models, porous membranes were used to
simulate the BBB, but in the recent models, BrOC-compatible
hydrogel channels have been placed as barriers for vascular trans-
port. The vascular networks formed in the hydrogel ducts are func-
tionally and structurally similar to the body vascular system and
increase the communication between the brain vascular cells and
the nerve cells. When the neural circuit and the vascular network
are placed together in a model, it increases axonal growth and
coordination of neural electrical activity (Osaki et al., 2018;
Sances et al., 2018).
Connecting several different chips is another way to study dif-
ferent parts of an organ or the physiological and pharmacological
interaction of several organs. Therefore, by connecting multiple
chips on a single platform, it is possible to simulate several func-
tions of an organ or connect several organs. The process of design-
ing and connecting multiple organs on a chip and building a multi-
chip system to simulate the interaction between different cells or
organs is in progress. These systems connect several organs on
the chip and flow the culture medium to facilitate cellular and tis-
sue interactions (Maoz et al., 2018). Newer models use the connec-
tion of multiple brain chips (membrane type) to study the
connection between different brain cells. Also, to study the inter-
cellular communication of the brain with different organs, the con-
nection of several organ chips is used together (Oleaga et al., 2016;
Vernetti et al., 2017). Various platforms have been developed and
used to study the cerebral vascular system, neural network, and
myelination.
To simulate the structure and physiology of brain tissues accu-
rately on a BrOC, three important factors must be considered: (i)
cell source, (ii) cell–cell interaction, and (iii) cell-matrix interac-
Fig. 5. (A, B, and C) BrOC model using two chambers and a porous membrane between them and culturing endothelial cells in the upper chamber and astrocytes in the lower
chamber, the BBB is simulated on a platform, (D and E) a segmented BrOC model with a cylindrical structure that can study neuronal growth, neural connections, and
myelination in detail, and (F) isolation steps of different parts of neurons for detailed study in a BrOC model.
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sonalized drugs is to extract cells from human resources. As the
cellular functions and genetic characteristics of animal cells are dif-
ferent from human cells and extracting early human cells is diffi-
cult, therefore, the iPSCs are a good source of human cells
(Takahashi and Yamanaka, 2006). The iPSCs may be obtained by
stimulating stromal cells with key growth factors and then differ-
entiating them into the cell of our interest. Because of the preser-
vation of genetic information of cells during induction and
differentiation, the production of personalized drugs will be possi-
ble (Singh et al., 2015). Patient-specific BBB models are currently
designed that use the patient’s iPSCs. These models make it possi-
ble to prepare a patient-specific medication (Vatine et al., 2019). In
Alzheimer’s disease, microglial cells are activated by beta-amyloid
as an active marker. Microglia cells accelerate neuronal death by
interacting with nerve cells via neurotoxic inflammatory agents
and microglia activators (Park et al., 2018a; Park et al., 2018b).
Due to the direct observation of the cell population in the organ-
on-a-chip technology, it is possible to study the response of each
cell type to develop drugs. On the other hand, it is possible to com-
mercialize the drugs by choosing effective drugs and minimizing
undesirable side effects. The extracellular matrix is a key factor
in the physical adhesion and transmission of messages between
cells. Therefore, it is necessary to determine which component of
the extracellular matrix should be used for in vitro culture
(Boudreau and Bissell, 1998). The cellular matrix of the brain can
be used for neurons produced by direct reprogramming. The neu-
rons cultured in a cellular matrix of the brain are differentiated
better than traditional 2D culture and collagen-based 3D culture.
This method also ensures the structural integrity and functional
maturity of the neurons (Jin et al., 2018). Accurate simulation of
the tissue environment is necessary to improve cell interaction
with the extracellular matrix.
Various models have been designed using microfluidics and
microfabricated technology that are used to study various diseases
of the nervous system. It is not currently possible to study the
entire nervous system on one model, the only way to study this
complex system is to design models that simulate parts of the sys-
tem’s activity. So far, various platforms have been developed to9
study the cerebral vascular system, neural network, and myelina-
tion. The connection of several platforms was used to study various
brain activities. With the advancement of technology, hydrogel-
based platforms were used for implanting different components
of the nervous system.
Due to the lack of physiologically-relevant brain tumors models
and unclear mechanism of progression and resistance, increasing
computational and in vitro modeling are developing for preclinical
prediction. Using minitumors with physiologically relevant vascu-
larized environment, decrypting mechanisms of brain tumors and
speed up the drug development and prediction of response to anti-
cancer agents (Clarke et al., 2021). Numerous bioengineered 3D
platforms including collagen, gelatin and hyaluronan have been
produced to assess the responses of patient-derived brain tumor
(Neves et al., 2021). Immaturity, need for validation and high
reproducibility are some of the challenges for biofabrication tech-
nologies (Clarke et al., 2021).
3.5. Liver-on-a-chip (LiOC)
Parenchymal cells (hepatocytes) and non-parenchymal cells
(endothelial, Kupffer, satellite cells, and bile epithelial cells) make
up 60 and 40% of the liver cells, respectively. The most important
physiological function of the liver is related to hepatocytes. Hepa-
tocytes are involved in many physiological processes such as syn-
thesis (bile, plasma proteins, urea, and glucose), storage (glucose,
iron, and vitamins), metabolism (amino acids), breakdown (xeno-
biotics and drugs), and detoxification of various substances
(LeCluyse et al., 2012; Materne et al., 2013). Non-parenchymal cells
maintain tissue structure, regulate physiological processes, and
modulate the phenotype of liver cells. The main non-
parenchymal cells are sinusoidal endothelial cells, and by creating
a unique tubular structure in the walls of the sinuses, they cause
the optimal exchange of substances between the blood flow and
hepatocytes (Poisson et al., 2017). The Kupffer cells are the specific
macrophages of the liver with a frequency of 12%. These cells kill
the microorganisms in the liver sinusoids by phagocytosis and
neutralize the toxic effects (xenobiotics, drugs, and toxins) by
endocytosis. They also activate the immune system and other cells
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cells, with a frequency of 1.4% of non-parenchymal liver cells, are
responsible for storing Vitamin A and fat droplets and regulating
microcirculation. They are also the most important cause of liver
fibrosis (Maschmeyer et al., 2011; Huang et al., 2017). The bile
epithelial cells line the walls of the bile ducts. These cells modify
the bile made by the liver cells through complex chemical and
physiological processes. Recent studies have identified their role
in hepatotoxicity and cholestatic liver disease (Masyuk et al.,
2018).
In vitro liver models are critical for hepatology studies and drug
development for liver diseases. An important aspect of these mod-
els is the cell source. There are three major types of cells to rebuild
liver tissue in vitro: primary human hepatocytes, hepatic-derived
cell lines, and stem cell-derived hepatocytes (Prot et al., 2011;
Garnier et al., 2018). Hepatic cell lines, such as HepG2 (derived
from human hepatocellular carcinoma of a 15-year-old male) and
HepaRG (terminally differentiated hepatic cells derived from a
hepatic progenitor cell line of a female hepatocarcinoma), have
been widely used in toxicological investigations because they have
a stable phenotype and are easily manipulated with the unlimited
proliferation (Desai et al., 2017; Weltin et al., 2017). By differenti-
ating induced pluripotent stem cells into the liver cells, hepatic
organoids are made that have physiological functions of hepatic
tissue such as urea production, albumin secretion, liver-specific
metabolic activities, and gene expression (Foster et al., 2019).
The LiOC systems are used for recognizing physiological pro-
cesses, screening and testing for drug toxicity, predicting drug
metabolism, establishing models for liver disease, and constructing
multi-organs-on-a-chip (Deng et al., 2019). The standard factors (s-
tandard liver cells and standard metabolic responses) are used to
screen and determine the responses of the liver towards the drug
compounds. For example, cytochrome P450 (CYP) enzyme levels
are a standard factor in analyzing the metabolism of hepatocytes.
Although cultured hepatocytes and native hepatocytes have phe-
notypic and metabolic differences, the levels of CYP enzymes are
not different in vitro and in vivo. In addition, they are often unaf-
fected by the chemical stimuli in vitro (Wrighton and Stevens,
1992; Shoemaker et al., 2020).
Au et al. (2014) designed a digital microfluidic device for cultur-
ing and producing three-dimensional liver tissues. Inhibitors and
inducers of CYP activity were used to perform enzymatic tests
and determine acetaminophen-induced hepatotoxicity. In this
study, significant changes in the enzymatic activities were
observed in cultured 3D tissues. But these changes were not
observed in the standard hepatocytes monolayer models. These
results showed that environmental conditions and the 3D geome-
try of tissues affected the enzymatic activities and physiological
functions of the tissues. Probably, different environmental and
geometric conditions in in vitro systems are responsible for these
differences, and cell–cell, as well as cell-extracellular matrix inter-
action, is better established in 3D than in 2D culture medium.
Another valuable strategy for engineering an in vivo liver model
for drug screening and other studies is to mimic the architecture of
the hepatic lobule in terms of the contribution of the different
types of cells that make up the lobule. Co-culture of hepatocytes
with other liver cells increases the efficiency of in vitro liver models
(Soldatow et al., 2013). The most important cells that interact with
the hepatocytes are endothelial cells, non-parenchymal cells such
as fibroblasts, Kupffer cells, and hepatic stellate cells (Kang et al.,
2013; Zhou et al., 2015). Designing the exact architecture of liver
tissues (size and geometry of building blocks) and using key factors
in liver cells (presence of all tissue-forming cells and continuous
flow through the vascular-like network) is an important step in
providing advanced models for studying the physiological func-10tions of the liver and understanding biochemical mechanisms in
the clearance and screening of drug compounds.
Ma et al. (2016) designed a microdevice to simulate the place-
ment of hepatocytes and endothelial cells in a liver lobule. Hepato-
cytes and endothelial cells were cultured radially on 3D hydrogels.
Endothelial cells that formed a hepatic sinusoid-like structure were
located in radial structures with hepatocytes. Hepatocytes cultured
in this device exhibited higher baseline CYP activity, compared to
standard hepatocytes controlled under standard conditions. Stan-
dard conditions include 2D culture of hepatocytes or culture of
hepatocytes alone in 3D hydrogels (Fig. 6).
Another key physiological aspect is the continuous perfusion of
cultured cells. Blood flow in vivo continuously cools liver cells, pro-
vides nutrients, and eliminates waste products. However, standard
cell culture media are not able to produce these characteristics
in vitro. Lack of constant flow in a standard cell culture medium
causes unstable conditions such as reduction of nutrients, increase
productions of waste materials, and elevation of tissue tempera-
ture. Creating a constant medium flow in the cell culture media
and organ-on-a-chip devices by creating stable environmental con-
ditions have improved tissue function and increased cell survival
(Lee et al., 2007; Baudoin et al., 2014).
In a project to determine the mechanisms associated with liver
cancer metastasis, a liver-on-a-chip model was designed to inves-
tigate how tumor-derived extracellular vesicles affect liver metas-
tasis. Extracellular vesicles are cell-derived membrane vesicles that
are secreted in almost all cell types, including cancer cells. The use
of this liver-on-a-chip technique showed that high levels of TGFb1
in the extracellular vesicles derived from breast cancer-induced
liver metastasis by increasing greater adhesion of breast cancer
cells to the sinus endothelial cells of the liver (Kim et al., 2020).
The functional units of the liver are the lobules. The hepatic lob-
ule consists of a central canal, the radial columns, and sinusoids
between the columns. Blood from the portal vein and hepatic
artery (from the periphery to the center of the lobule) enters the
central canal through the sinusoids. The blood in the central canal
then enters the vena cava through the hepatic vein. The lobular
radial columns are made up of hepatocytes and bile ducts exist
inside these columns. There is an opposite current (from the center
to the periphery of the lobule) inside the radial columns of the lob-
ule that enters the bile made by hepatocytes through the canals
into the bile ducts. The bile ducts are connected and bile enters
the gallbladder.
In most liver-on-a-chip models, several important physiological
points, such as the bile secretion process, bile duct architecture,
and bile flow direction in the hepatic lobule are not considered.
Bile is the most important secretory substance in the liver, and
most chemicals and drugs are converted to water-soluble sub-
stances by complex liver mechanisms and then secreted into the
bile. Therefore, mixing hepatocyte secretions with other sub-
stances in the medium prevents the correct extraction of informa-
tion and the results of these models are challenged in terms of
validity. However, the model proposed by Ma et al. (2016) seems
to be the best and closest model for simulating the structure of
hepatic lobule provided that the bile flow is separated from the
medium flow. Hence, to separate the bile flow from the medium,
in this model, channels can be created in the area between the cen-
ter and periphery of the lobule.
The perisinusoidal space is the area in the liver between the
hepatocytes and the sinusoidal endothelium that contains blood
plasma. Hepatocyte microvilli expand into this space, allowing
proteins and other plasma components to be absorbed by the hep-
atocytes from the sinusoids. The presence of pores and discontinu-
ities in the endothelium, as well as its basement membrane,
facilitates this transmission. This space may be lost in liver disease,
Fig. 6. LiOC model. (A) a lobule-on-chip model was designed on a radial platform. Hepatocytes were cultured with endothelial cells, (B) a LiOC (sinusoid-on-chip) in which
hepatocytes were cultured in a cell chamber and sinusoidal-like pores were used to simulate vascular endothelium, and (C) this LiOC model used all the cells that make up the
liver lobule, a porous membrane between two chambers (upper and lower), and two opposing medium currents (in two chambers).
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waste products such as bilirubin by hepatocytes. The perisinu-
soidal space plays a key role in the function of hepatocytes and
prevents the rapid flow of interstitial fluid and rapid changes in
the areas around hepatocytes (Sanz-García et al., 2021).
In a LiOC model proposed by Boeri et al. (2019), two chambers
were separated using a permeable membrane. Endothelial cells
were cultured with Kupffer cells in the upper chamber and hepato-
cytes with the stellate cells in the lower chamber. Inside these two
chambers, two medium currents were circulated in opposite direc-
tions. This design was able to prevent the mixing of the sinusoidal
space medium and the bile duct (Fig. 6). But in this model, the per-
meable membrane between the sinusoidal endothelium and the
hepatocytes cannot simulate the perisinusoidal space. It seems
that another membrane or scaffold can be used to solve this prob-
lem and create space. Also, to improve the performance of the
model, a collagen scaffold can be used instead of a polymer
membrane.
Hepatocellular carcinoma-on-chip models have been utilized to
assess the effect of tumor microenvironment conditions on the via-
bility of tumor-specific T cell receptor (TCR) expressing T cells
(Clapp et al., 2021). This model has been successfully used to eval-
uate the effect of inflammation and hypoxia (tumor-related niche
condition) on the cytotoxicity of the aforementioned cells. Accord-
ing to the result hypoxia diminished the functionality of cells and
the inflammatory condition resulted in optimal T cell-mediated
cytotoxicity (Clapp et al., 2021)
3.6. Bone marrow-on-a-chip
Hematotoxicity is a remarkable issue, in which various circulat-
ing mature blood cells or immature sensitive ones in the bone mar-
row are targeted by direct or indirect cytotoxicity from chemical
compounds, such as drugs and other xenobiotics (Mahalingaiah
et al., 2018). The evaluation of hematotoxicity as a routine part
of drug safety assessment for early pre-clinical development and
investigative hematopathology process is very critical because
toxic effects to the hematopoietic system result in human severe11damage due to myelosuppression, pancytopenia, infection, or clot-
ting deficiencies (Gödel et al., 2021). Despite the straightforward
monitoring of hematotoxicity, it is sometimes associated with sev-
ere complications, therefore this process is mainly performed in a
therapeutic area or in vitro situation, which has a high profit-loss
ratio. Due to the high proliferation rate and constant differentia-
tion of immature blood cells in the bone marrow, as well as the
giant diversity of the cells, which are in different stages of differen-
tiation, it is not surprising that the effect of the toxicant on the cells
would be cell-type selective related to their sensitivity to the drugs
(Skaggs et al., 2019). Given the various mechanism of hematotox-
icity on the hematopoietic stem cells, many protocols have been
extended.
Given that the hematopoietic stem cells (HSCs) of the bone mar-
row have a rapid rate of proliferation and renewal, they could
strongly be affected by the adverse effects of chemical compounds,
which targeted their proliferation, differentiation, and function
from the progenitors to the mature cells (Ruiz-Argüelles et al.,
2018). Previously, for preclinical toxicity studies, different labora-
tory animals were used, which were associated with many limita-
tions. In another developed model as a humanized bone marrow
xenograft system, immunodeficient mice were transplanted with
human CD34 cells, and the toxicity of the drugs was assessed on
the human hematopoietic stem cells in vivo by examining the
human mature chimeric cells in the peripheral blood of the mice
(Martinov et al., 2021). The major differences between the drug
sensitivity of the mouse- and human-derived cells were one of
the main limitations of this model (Lõhmussaar et al., 2020). Sub-
sequently, to bridge the gap between animal and clinical investiga-
tions, various in vitro methods were examined with desirable
results (Kolle and Landsiedel, 2020). To gain more accurate and
closer results to the human-species clinical context, as well as to
reduce the rate of species-specific cross-reactive reagents and the
number of animals used, it is worthy to apply the human base
hematotoxicity assays, which employs human cells such as bone
marrow or umbilical cord blood cells in vitro (Starling et al., 2020).
Various systems have been studied to achieve truthful and com-
mercially viable in vitro assays for the evaluation of hematotoxicity
Fig. 7. 3D model of the bone marrow-on-a-chip device consisting of the upper cell culture microchamber layer and the lower medium perfusion microchamber layer, which
are separated by a porous membrane.
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assessment in human hematopoietic stem cells, two transcription
factors (GATA2 and ETV2) were induced in human pluripotent
stem cells (hiPSCs) to differentiate the cells to myeloid-
hematopoietic ones in a suspension medium through a lentivirus
(Elcheva et al., 2014; Slukvin and Uenishi, 2019). The test items
were applied to the cells during the differentiation and the various
adverse effects of the chemical compounds were studied by evalu-
ating the cell surface markers fluctuation, viability, and analysis of
target gene expression (Elcheva et al., 2014). These transcription
factor-based differentiation systems provided a useful platform,
which allowed monitoring the effects and mechanisms of myelo-
suppressive drugs on hiPSC-derived myeloid progenitor cells
(Elcheva et al., 2014).
Unreliability of the animal models as a preclinical pattern and
the failure of the 2D cell culture models to simulate dynamic
modes of the native cellular microenvironment has led to the
establishment of various 3D models in the evaluation of hemato-
toxicity (Dehne et al., 2019). Among the various developed meth-
ods, the bone marrow-on-chip model is considered a clinically-
reliable model (Aleman et al., 2019). The human bone marrow-
on-a-chip system as a micro physiological system (MPS) is an
advanced in vitro model of the hematotoxicity assessment proce-
dure, which uses 3D culturing methods and specific extracellular
matrix ingredients with constant media perfusion that provide
them to keep homeostasis (Dehne et al., 2019; Maharjan et al.,
2020; Kefallinou et al., 2020). This artificial niche scaffold co-
culture with stromal and mesenchymal cells (MSCs) mimics the
in vivo biological properties under in vitro conditions (Bui et al.,
2021). Given that the hematopoietic stem/progenitor cells (HSPCs)
can sustain for prolonged culture periods in the in vivo-like
microenvironment system, the effects of a chemical compound
could be comprehensively evaluated, even in very late-stage mat-
uration of the cells (Zhang et al., 2017a; Zhang et al., 2017b; Nies
and Gottwald, 2017). To provide a more physiological relevance
and increase the promoting factors in the system, vascular bed
and further cell type could be added (Cochrane et al., 2019). To
investigate the effects of the various metabolites on the HSPCs in
bone marrow-on- a chip devices, the bone marrow model is co-
cultured with the other organ models (Geraili et al., 2018). So far,
different devices of the bone marrow-on-chip system have been12developed. In such a model, the upper cell culture contained a
cylindrical-shaped microchamber, detached from the lower med-
ium perfusion one with a 20 lm thickness poly dimethyl siloxane
porous membrane (Kefallinou et al., 2020). The median membrane
with 6–8 lm pores not only acts as a dwelling for the MSCs but
also allows the cells to be continuously nourished from the lower
medium perfusion microchamber. The whole structure is sealed
with the glass slide at the upper microchamber layer to monitor
the expansion of the cells using a microscope. In this system, the
MSCs are initially cultured in the upper microchamber to expand
the stromal cell-matrix and subsequently to host the HSCs
(Fig. 7) (Kefallinou et al., 2020).
Although MPS-based hematotoxicity screening is a comprehen-
sive method to assay the toxicity of the drugs on the bone marrow
hematopoietic stem cells, major challenges are involved in it
(Lõhmussaar et al., 2020). Due to the extensive intercellular signal-
ing and high complexity of the bone marrow niche, the repro-
ducibility of a microenvironment similar to in vitro conditions is
very troublous (Dehne et al., 2019). At present, in the field of
MPS research, high efforts are being made to execute the body-
on-a chip model as well as to set up the patient’s bone marrow-
on-a chip to evaluate the therapeutic effects of various drugs on
the cells in the system.4. Organ-on-a-chip technologies: Why are they necessary?
Microfluidics technologies are considered a gigantic step
towards biomedicine. No doubt, the extraction of extensive infor-
mation regarding biological systems requires novel innovations
in biomedicine. In this regard, the organ-on-a-chip system has
been proved as an emerging technology and helped understand
the biological processes at the molecular level. This device has
shown great potentiality to alter the healthcare system worldwide.
The Organ-on-a-chip system is playing a paramount role in health-
care due to its rapid analyses characteristics as compared to the
other traditional biomedical techniques. High data processing
and storage approaches can be achieved by microfluidics tech-
niques. In addition, this technology not only reduces the necessity
of more reagents and bulky equipment but also saves time for per-
forming extensive procedures while maintaining the sensitivity
and specificity of conventional protocols. In a like manner, these
S. Seidi, A. Eftekhari, A. Khusro et al. Journal of King Saud University – Science 34 (2022) 101710miniaturized devices may contribute an auspicious role in the
healthcare systems of developing nations by providing cost-
effective and sophisticated analytical tools, especially in the con-
text of the Sustainable Development Goals (SDGs). Despite the
lower ability to recreate the complex nervous, immune, and endo-
crine systems as compared to the in vivo models, the organ-on-a-
chip system may transform the biomedical field in the next few
years due to its pronounced applications viz. high throughput
drugs screening, therapeutics, biosensing and diagnostics.
5. Future perspectives
The extensive applications of organ-on-a-chip systems may
provide a significant opportunity to model and explore different
organs that have yet to be studied in their desired fields. Organ-
on-a-chip biosystem has shown enormous advantages over
in vivo model organisms. Currently, traditional cell culture meth-
ods are unable to provide controlled stimuli for stem cells.
Organ-on-a-chip technology may not only establish new
approaches for studying the differentiation of stem cells but also
improve the existing stem cell therapy. In addition, these devices
may provide an efficacious platform for investigating the genetic
state of stem cells in the future by maintaining an ideal microenvi-
ronment. It is proposed that organ-on-a-chip technologies may be
used in developing several human-disease models including pedi-
atric and other rare diseases. Of note, designing and applications of
human-body-on-a-chip would be the pivotal applications of organ-
on-a-chip biosystems in the near future.
6. Conclusions
Organ-on-a-chip technologies have shown significant ability to
translate in vitro studies into clinical research. Given the potential-
ity to maintain the organs’ microenvironment, this microfluidic
device has been proved as a primary model to investigate the phar-
macological attributes of specific drugs of interest. Several organ-
on-a-chip systems have been prepared and the technology is creat-
ing a strong partnership between academia and industries. These
microfluidics technologies may play decisive roles and pose an
absolute platform in the discovery of effective drugs for vital
organs associated with deadly diseases in a limited time. They
can also be linked with an actuator system for on-demand or
non-stop drug release. Microfluidics have opened new avenues in
the fabrication of drug carriers and the development of direct drug
administration chips. Manufacturing drug carriers that can pro-
duce a repeatable release pattern as well as the controlled release
of several agents with different release profiles requires the appli-
cation of microfluidic technology. In a nutshell, organ-on-a-chip
technology is creating an exquisite picture of tissue engineering
for establishing the foundation of a new era in the field of
biomedicine.
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